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Summary
‘‘Oncogene addiction’’ describes an unexplained dependency of cancer cells on a particular cellular pathway for survival or
proliferation. We report that differential attenuation rates of prosurvival and proapoptotic signals in oncogene-dependent
cells contribute to cell death following oncogene inactivation. Src-, BCR-ABL-, and EGF receptor-dependent cells exhibit
a similar profile of signal attenuation following oncogene inactivation characterized by rapid diminution of phospho-ERK,
-Akt, and -STAT3/5, and a delayed accumulation of the proapoptotic effector phospho-p38 MAPK. These findings implicate
a transient imbalance in survival and apoptotic oncogenic outputs in the apoptotic response to oncogene inactivation.
Moreover, these observations implicate a common profile of signal attenuation for multiple oncogenes and suggest that
‘‘addiction’’ associated with apoptosis reflects an active rather than a passive process.Introduction
‘‘Oncogene addiction’’ is a term that was first coined by Bernard
Weinstein to describe the apparent acquisition of dependency
by tumor cells on a single oncogenic activity (Weinstein, 2000,
2002; Weinstein et al., 1997). This phenomenon has been
most clearly illustrated in several different transgenic mouse
models of tumorigenesis and is characterized by the prolifera-
tive arrest, differentiation, and/or apoptosis of tumor cells upon
the acute inactivation of an oncogene that initially contributed
to the tumor phenotype. For example, in a leukemic model in
which inducible transgenic Myc overexpression causes T cell
and myeloid leukemias, switching off the Myc oncogene causes
tumor cells to undergo growth arrest, differentiation, and apo-
ptotic cell death (Felsher and Bishop, 1999). Similarly, in a trans-
genic model of BCR-ABL-induced leukemia, switching off the
transgene results in rapid apoptosis of leukemic cells (Huettner
et al., 2000). The oncogene addiction phenomenon appears to
apply to solid tumors as well, since in a model of conditional
transgenic H-Ras-induced mouse melanomas, turning off the
activated Ras gene causes massive apoptosis within tumors
(Chin et al., 1999).
In addition to these transgenic oncogene models, cell culture
studies of human cancer cells have further substantiated theCANCER CELL 10, 425–435, NOVEMBER 2006 ª2006 ELSEVIER INC. DOconcept that tumor cells can become dependent on a single on-
cogenic pathway for their sustained proliferation or survival. For
example, human pancreatic cancer cell lines harboring a muta-
tionally activated K-Ras oncogene can be growth inhibited
by introducing antisense K-Ras oligonucleotides (Aoki et al.,
1997). Similarly, selective kinase inhibitors such as imatinib
(Gleevec), which targets the BCR-ABL fusion kinase (Druker
et al., 1996; Gambacorti-Passerini et al., 1997), or gefitinib
(Iressa) or erlotinib (Tarceva), which target the EGF receptor
kinase (Mukohara et al., 2005), can efficiently kill a subset of
cultured tumor cells that express those oncogenes. Such find-
ings seem to indicate that many tumor cells, despite the accu-
mulation of multiple genetic alterations, retain dependency on
a limited number of oncogenes that initially drove them to a
malignant phenotype.
The apparent dependency on individual oncogenes exhibited
by tumor cells potentially reveals an ‘‘Achilles’ heel,’’ or vulner-
able point, within such cells that renders them susceptible to
the activities of antitumor agents that selectively target these
oncogene products (Weinstein, 2002). Indeed, examples of
dramatic clinical response have been observed in a subset of
BCR-ABL-positive chronic myelogenous leukemia patients
treated with imatinib (O’Dwyer et al., 2003). Similarly, a subset
of patients with non-small cell lung cancer, where mutationallyS I G N I F I C A N C E
The phenomenon of ‘‘oncogene addiction’’ has now been well documented in multiple mouse tumor models and cancer cell lines.
Moreover, oncogene addiction may account for the dramatic clinical responses reported in some cancer patients treated with tar-
geted kinase inhibitors. However, a molecular mechanism to explain oncogene addiction has been elusive. Our findings suggest
that differential decay rates of prosurvival and proapoptotic signals emanating from an oncoprotein, such as an activated kinase,
can contribute to tumor cell death following acute inactivation of an oncogene upon which they have become dependent. Our find-
ings attempt to provide a molecular mechanism for oncogene dependency, and they may have important implications for the ther-
apeutic use of targeted kinase inhibitors.I 10.1016/j.ccr.2006.09.014 425
A R T I C L Eactivated or amplified EGF receptors are sometimes observed,
exhibit striking clinical responses to gefitinib and erlotinib (Lynch
et al., 2004; Paez et al., 2004; Pao et al., 2004). It is believed that
such responses similarly reflect the phenomenon of oncogene
addiction, thereby highlighting its importance in the context of
cancer therapeutics that target activated oncoproteins.
Despite accumulating evidence (largely derived from trans-
genic mouse models, cell culture studies of human cancer cell
lines, and clinical studies of targeted kinase inhibitors) that on-
cogene addiction is a widespread and important phenomenon,
a molecular mechanism to explain it has yet to be clearly eluci-
dated. It has been suggested that the ‘‘circuitry’’ of a cancer cell
has somehow been corrupted such that it acquires a depen-
dency on signaling pathways that are not normally required in
the cell from which the tumor cell was derived (Weinstein,
2002). This could certainly be true, although it has been difficult
to prove this experimentally. We have recently proposed a re-
lated but distinct hypothesis to explain oncogene addiction
(Sharma et al., 2006). We propose that differential attenuation
rates among the multiple proapoptotic and prosurvival signals
emanating from an activated oncogene result in a transient
imbalance in signaling. This imbalance results from the fact
that survival signals are relatively short-lived following acute
inactivation of the oncogene, while proapoptotic signals persist
sufficiently long to produce an apoptotic outcome. To test this
theoretical model experimentally, we have examined the
attenuation kinetics of known survival effectors following the
inactivation of the Src, BCR-ABL, and EGF receptor oncogenes
in several cell culture models associated with oncogene depen-
dency. We determined that a common profile of signal attenua-
tion involving the ERK, Akt, and STAT3/5 proteins is associated
with oncogene inactivation in each of these cases, and that in
each setting, a temporally delayed accumulation of at least
one proapoptotic effector, phospho-p38 MAP kinase, is ob-
served. Based on these and additional findings described be-
low, we conclude that a shared mechanism of differential signal
attenuation can contribute to the oncogene addiction phenom-
enon in multiple different contexts.
Results
Modeling oncogene addiction in cells dependent
on the BCR-ABL oncogene
To model the phenomenon of oncogene addiction in cultured
cells, we took advantage of a previously described cell line,
TonB210.1, in which the BCR-ABL oncoprotein that is detected
in the vast majority of human chronic myelogenous leukemias
(CML), is expressed in a doxycycline-regulated manner (Klucher
et al., 1998). TonB210.1 cells were derived from an interleukin-3
(IL-3)-dependent hematopoietic cell line (BAF3), and expression
of the BCR-ABL protein in these cells renders them IL-3 inde-
pendent in a cell viability assay. As previously reported (Klucher
et al., 1998), these cells undergo massive apoptotic cell death
within 48–72 hr following disruption of BCR-ABL expression
(data not shown). This dependency on maintained BCR-ABL
survival signaling appears to model the well-established clinical
response to ABL kinase inhibitors seen in some CML patients.
We observed that levels of BCR-ABL protein in TonB210.1
cells begin to decline within 8 hr of doxycycline treatment (Fig-
ure 1), and this is accompanied by a concomitant decrease
in the phosphorylation of several major phospho-tyrosine-426containing proteins (including BCR-ABL itself), as revealed by
immunoblotting of cell lysates with a phospho-tyrosine antibody
(Figure 1). In these doxycycline-treated cells, morphologic indi-
cations of apoptosis become apparent within 8 hr of treatment,
and cleaved PARP, a marker of apoptosis, can also be detected
at this time point (data not shown). Between 24 and 48 hr follow-
ing treatment, massive apoptosis becomes evident, and the
vast majority of cells are dead within 72 hr. Thus, as previously
described, these cells are highly dependent on BCR-ABL
expression for their survival.
To determine the kinetics of signal attenuation associated
with known downstream mediators of cell survival in this setting,
we examined the phosphorylation status of Akt, STAT5, and
Figure 1. Modulation of signaling following acute Bcr-Abl inactivation in
TonB210.1 cells
Bcr-Abl was induced in TonB210.1 cells by doxycycline treatment for 18 hr.
Bcr-Abl was then inactivated by the removal of doxycycline, and at various
times postinactivation Bcr-Abl cells were harvested and their proteins were
analyzed by SDS-PAGE followed by western blotting using antibodies
directed against Bcr, phospho-tyrosine, phospho-Akt (P-Akt), Akt, phos-
pho-ERK1/2 (P-ERK1/2), ERK1/2, phospho-p38 (P-p38), and p38. Times postin-
activation of Bcr-Abl (in hours) are indicated at the top of each lane, the
relative migrations of the relevant proteins are indicated on the left-hand
side of each autoradiogram, and to the right of each autoradiogram are
indicated the relative migrations of molecular weight standards. In the
second panel, arrows point to several unidentified proteins whose tyrosine
phosphorylation appears to decrease upon Bcr-Abl inactivation.CANCER CELL NOVEMBER 2006
A R T I C L EERK1/2 (Steelman et al., 2004). As shown in Figure 1 (and data
not shown), each of these proteins is phosphorylated for as long
as BCR-ABL protein is active (up to 4 hr). At 8 hr post-doxycy-
cline treatment, concomitant with BCR-ABL inactivation, the
phosphorylation of each of the proteins is substantially dimin-
ished (Figure 1 and data not shown). Thus, these three ‘‘survival
effectors’’ are each rapidly inactivated following disruption of
BCR-ABL activity. We also examined the phosphorylation sta-
tus of the p38 MAP kinase, an established downstream target
of BCR-ABL that has been implicated in proapoptotic signaling
in some contexts (Bandyopadhyay et al., 2004). Interestingly,
while phospho-p38 MAP kinase levels are barely detectable
prior to BCR-ABL inactivation, a clear increase in phospho-
p38 is observed within 24 hr of doxycycline treatment, suggest-
ing that a temporally delayed activation of p38 contributes to the
apoptotic response that follows acute inactivation of BCR-ABL
(Figure 1).
Modeling oncogene addiction in cells dependent
on a mutationally activated EGF receptor
We next wanted to determine whether the inactivation of sur-
vival effectors and subsequent accumulation of activated p38
that was observed upon BCR-ABL inactivation could extend
to other cell culture models of oncogene dependency. There-
fore, we took advantage of another BAF3-derived cell line in
which expression of a mutationally activated form of the EGF re-
ceptor that has been detected in a subset of non-small cell lung
cancers confers IL-3-independent cell survival (Jiang et al.,
2005). In these cells, treatment with the selective EGF receptor
kinase inhibitor gefitinib results in the virtual complete inactiva-
tion of EGFR autophosphorylating activity within 4 hr, and mas-
sive apoptotic cell death within 72 hr, as previously reported
(Jiang et al., 2005) (Figure 2 and data not shown). As was seen
in the TonB210.1 cells upon inactivation of BCR-ABL, cleaved
PARP can be detected in these cells within 24 hr of EGFR inac-
tivation (Figure 2). Moreover, within 4 hr of gefitinib treatment,
levels of phospho-STAT5, -ERK1/2, and -Akt are all substantially
reduced (Figure 2), and between 8 and 24 hr, phospho-p38
levels accumulate (Figure 2). Thus, models of oncogene depen-
dency driven by either BCR-ABL or EGFR appear to involve
a shared mechanism of signal attenuation following oncogene
inactivation that involves the relatively rapid decay of survival
signaling followed by a delayed activation of the p38 proapop-
totic kinase.
Modeling Src kinase dependency using
a temperature-sensitive switch
Like BCR-ABL and EGFR kinases, the Src kinase has also been
implicated in human tumorigenesis and can also transduce pro-
survival as well as proapoptotic activities. This signaling duality
of Src has been most clearly demonstrated using a fibroblast
cell line in which a temperature-sensitive activated c-Src mutant
(Maroney et al., 1992) is expressed to produce a malignant phe-
notype associated with morphologic transformation (Johnson
et al., 2000). When cultured in 10% serum at 39.5C, the nonper-
missive temperature (Src is inactive), these cells exhibit a rela-
tively flat, nontransformed appearance in culture. When the tem-
perature is shifted to 35C, the permissive temperature, these
cells rapidly become spindle shaped and refractile, exhibiting
clear characteristics of Src-transformed fibroblasts (Figures
3A and 3B). When these cells are shifted to 39.5C, and theCANCER CELL NOVEMBER 2006serum concentration is reduced to 0.2%, substantial levels of
apoptosis are observed within 2 hr of the temperature shift
(Figures 3C and 3D). Significantly, the parental fibroblasts
from which these Src-transformed cells were derived do not
undergo apoptosis in reduced serum, even when shifted to
39.5C (data not shown). Thus, this cell culture model appears
to represent an additional setting in which an oncogene
addiction-like phenomenon is involved.
By examining phospho-proteins in these cells following acute
Src inactivation, we determined that, within 30 min of Src
Figure 2. Modulation of signaling following acute EGFR(L858R) inactivation
in BaF3-EGFR(L858R) cells
BaF3-EGFR(L858R) cells constitutively express the L858R-activating mutation
in EGFR, which renders the BaF3 cells independent of IL-3. EGFR(L858R) was
inactivated by treating cells with 2 mM of gefitinib, and at various times
posttreatment cells were harvested and their proteins were analyzed
by SDS-PAGE followed by western blotting using antibodies directed
against phospho-tyrosine (P-Tyr proteins), phospho-EGFRY1068 (P-EGFR),
EGFR, cleaved PARP (cl-PARP), full-length PARP (fl-PARP), phospho-STAT5
(P-STAT5), STAT5, phospho-ERK1/2 (P-ERK1/2), ERK1/2, phospho-Akt (P-Akt),
Akt, phospho-p38 (P-p38), and p38. Times posttreatment with gefitinib (in
hours) are indicated at the top of each lane, the relative migrations of
the relevant proteins are indicated on the left-hand side of each autoradio-
gram, and to the right of each autoradiogram are indicated the relative
migrations of molecular weight standards. In the top panel, arrows point
to several unidentified proteins whose tyrosine phosphorylation appears to
decrease upon v-src inactivation.427
A R T I C L Einactivation, levels of phospho-tyrosinated proteins rapidly be-
gin to decline (Figure 4A), cleaved PARP begins to accumulate
(Figure 4A), and levels of phospho-STAT3, -Akt, and -ERK1/2
are substantially diminished (Figure 4A). Moreover, levels of
phospho-p38 begin to increase within 1 hr of Src inactivation
and continue to increase until about 6 hr following temperature
shift (Figure 4A).
To verify independently that the observed signaling changes
following temperature shift truly reflect the consequences of
Src inactivation, analogous studies were performed using a
selective small molecule inhibitor of the Src kinase, SU-6656
(Blake et al., 2000). 3T3 mouse fibroblasts that had been trans-
formed with a viral form of activated Src begin to exhibit apopto-
tic characteristics within 2 hr of treatment with SU-6656 and
exhibit similar changes in the phosphorylation of STAT3, Akt,
ERK1/2, and p38 proteins as seen in cells transformed by the
Figure 3. Morphological alterations induced by changes in serum and tem-
perature in Balb-A1 ts-Src cells
A: Balb-A1 ts-Src cells growing in 10% serum-containing medium at 35C
display the typical transformed morphology of Src-transformed cells.
B: Overnight incubation at 39.5C in the presence of 10% serum causes the
cells to revert to a normal morphology.
C: Shown at a slightly higher magnification are Balb-A1 ts Src cells growing
overnight in 0.2% serum-containing medium at 35C.
D: When cells shown in C were shifted to 39.5C (in 0.2% serum), cellular
apoptosis was evident (indicated by jagged arrows) within 2 hr after the
temperature shift.
E: Morphology of Balb-A1 ts-Src cells maintained continuously at 39.5C in
the presence of 10% serum, after 15 passages.428temperature-sensitive Src mutant upon shift to the nonpermis-
sive temperature (Figure 4B). Thus, the regulated phosphoryla-
tion of these proteins exhibits a kinetic profile upon Src inactiva-
tion that is analogous to that seen upon acute disruption of the
BCR-ABL and activated EGFR kinases. Significantly, the signal-
ing changes and apoptotic effects of Src inhibition with SU-6656
are only revealed in the absence of serum, consistent with a se-
rum-provided survival signal that protects cells from the apopto-
tic output from oncogenic Src acutely following its inactivation
(Figures S1 and S2 in the Supplemental Data available with
this article online). Moreover, NIH3T3 cells expressing endoge-
nous wild-type Src are unaffected by SU-6656 treatment even in
the absence of serum, indicating that the observed apoptotic
response is dependent on an output from oncogenic Src (Fig-
ure S3). Taken together, these findings suggest that a shared
signaling cascade may contribute to ‘‘addiction’’ to Src, BCR-
ABL, and EGFR kinases in cell culture models.
Testing the model in a human tumor cell line
The three models of oncogene dependency described above
are somewhat artificial in that they involve the introduction of
a single oncogene into a cell type that may not correspond
closely with the cell type that is malignantly transformed by
the oncogene in the context of human tumorigenesis. Therefore,
we performed a similar analysis of a human tumor-derived cell
line that exhibits features associated with oncogene addiction.
Specifically, we used the PC-9 human non-small cell lung can-
cer line, which harbors an activating mutation within the EGF re-
ceptor gene, and has been found to be exquisitely sensitive to
the effects of gefitinib in a cell viability assay (Ono et al., 2004).
Thus, 2 mM gefitinib kills the vast majority of these cells within
72 hr of treatment (Figure 5A), with levels of phospho-EGFR rap-
idly depleted within 4 hr of treatment (Figure 5B) and levels of
cleaved PARP detectable within 8 hr of treatment (Figure 5B).
We observed that levels of phospho-Akt and phospho-ERK1/2
in PC-9 cells are substantially diminished within 4 hr of gefitinib
exposure (Figure 5B). Notably, phospho-Akt levels partially re-
cover prior to apoptosis, consistent with the signal attenuation
model described in the next section. Moreover, levels of phos-
pho-p38 are observed to increase significantly beginning at 4
hr following gefitinib treatment, peaking by 8 hr, and persisting
for 36 hr (Figure 5B). Hence, a profile of signal attenuation
among these proteins is seen in gefitinib-treated human lung
cancer cells and appears to be quite similar to the profile ob-
served in each of the three models described above.
Oncogene addiction may reflect the timing
of signal attenuation
Since we observed that acute inactivation of Src, BCR-ABL, and
EGFR oncogenes results in the rapid diminution of several cell
survival effectors and the subsequent engagement of at least
one proapoptotic effector, we wanted to examine a hypothesis
that the apoptotic response to oncogene inactivation in these
settings actually reflects a transient imbalance between prosur-
vival and proapoptotic signaling. To test this hypothesis, we uti-
lized the temperature-sensitive Src-transformed cells, in which
Src activity can be reversibly regulated. We reasoned that, if ap-
optosis in these cells following Src inactivation results from sus-
tained proapoptotic signaling downstream of Src following rapid
loss of prosurvival signals, it might be possible to ‘‘protect’’CANCER CELL NOVEMBER 2006
A R T I C L EFigure 4. Modulation of signaling following
acute Src inactivation in Balb-A1 ts-Src cells
and c2 v-Src 3T3 cells
A: The ts-Src oncoprotein was inactivated in
serum-starved Balb-A1 ts-Src cells by shifting cells
to 39.5C. At various times postinactivation of
Src, cells were harvested and their proteins
were analyzed by SDS-PAGE followed by west-
ern blotting using antibodies directed against
phospho-tyrosine (P-Tyr proteins), cleaved PARP
(cl-PARP), phospho-STAT3 (P-STAT3), STAT3, phos-
pho-Akt (P-Akt), Akt, phospho-ERK1/2 (P-ERK1/2),
ERK1/2, phospho-p38 (P-p38), and p38. Times
postinactivation of Src (in minutes and hours)
are indicated at the top of each lane, the rela-
tive migrations of the relevant proteins are indi-
cated on the left-hand side of each autoradio-
gram, and to the right of each autoradiogram
are indicated the relative migrations of molecu-
lar weight standards.
B: V-src oncoprotein was inactivated in serum-
starved c2 v-Src 3T3 cells by the addition of
3 mM of SU-6656, a src-specific inhibitor. At various
times postinactivation of Src, cells were har-
vested and their proteins were analyzed by
SDS-PAGE followed by western blotting using an-
tibodies directed against phospho-tyrosine (P-Tyr
proteins), activated phospho-src (P-Src), total
src, cleaved PARP (cl-PARP), full-length PARP
(fl-PARP), phospho-STAT3 (P-STAT3), STAT3, phos-
pho-Akt (P-Akt), Akt, phospho-ERK1/2 (P-RK1/2),
ERK1/2, phospho-p38 (P-p38), and p38. Times
postinactivation of Src (in minutes and hours)
are indicated at the top of each lane, the rela-
tive migrations of the relevant proteins are indi-
cated on the left-hand side of each autoradio-
gram, and to the right of each autoradiogram
are indicated the relative migrations of molecu-
lar weight standards. In the top panel, arrows
point to several unidentified proteins whose tyro-
sine phosphorylation appears to decrease upon
v-src inactivation.these cells from apoptosis following Src inactivation by culturing
them for a period of time in serum (the survival factor) at 39.5C
prior to reducing serum to levels that would otherwise cause
apoptosis in these cells.
First, we determined that inactivation of the PI-3 kinase/Akt
pathway using the PI-3 kinase inhibitor LY294002 in cells main-
tained at 35C in reduced serum (0.2%) causes a high percent-
age of cells to undergo apoptosis (Figure 6), indicating that
serum is providing a PI-3 kinase-dependent cell survival signal
in this context. Then, we observed that, when the Src-TS-trans-
formed cells are initially propagated at 35C (Src is activated)
and then shifted to 39.5C (Src is inactivated), they can be main-
tained in the presence of 10% serum indefinitely (Figure 3E).
Moreover, the cells can then be transferred to low serum con-
centrations while remaining viable and without indications of
apoptosis (data not shown). This finding clearly indicates that
these Src-transformed cells are not absolutely dependent on
Src activity for their survival and that they can be manipulated
in such a way as to suppress the apoptotic response that can
follow acute Src inactivation.CANCER CELL NOVEMBER 2006Signal attenuation following oncogene activation may
be temporally orchestrated via a phosphatase activity
The findings described above suggest that the kinetics of signal
attenuation following acute inactivation of these various onco-
genes contributes to the apoptotic response and that this could
result from a transient imbalance in prosurvival and proapop-
totic phosphorylation-mediated signaling. Moreover, the fact
that each of these three oncogenic kinases (Src, BCR-ABL,
and EGF receptor) has been reported to promote activation of
the p38 MAP kinase (Bandyopadhyay et al., 2004; Harper
et al., 2002; Turkson et al., 1999), and yet this kinase exhibits
an apparent delayed activation upon oncogene inactivation, rai-
ses the possibility that relief from a phosphatase activity that
suppresses levels of active phospho-p38 contributes to its
delayed accumulation in these settings. In other words, we hy-
pothesize that, while ‘‘steady-state’’ phospho-p38 levels appear
to be relatively low in each of these cells prior to oncogene inac-
tivation, this may reflect a dynamic balance between p38 phos-
phorylation and phosphatase-mediated dephosphorylation in
which the phosphatase activity predominates.429
A R T I C L ETo test this hypothesis, we treated the EGFR-transformed
BAF3 cells with the phosphatase inhibitor okadaic acid (OA),
which inhibits the PP2A phosphatase that has been previously
shown to regulate phospho-p38 levels (Lee et al., 2003). As
shown, OA treatment of these cells is sufficient to cause the ac-
cumulation of phospho-Akt, -ERK, and -p38 within 6 hr of treat-
ment (Figure 7A; lanes 1–4), suggesting that the activation
of these kinases is under negative regulatory control by an
OA-sensitive phosphatase. Note that levels of phospho-EGFR
eventually begin to decline, commensurate with the onset of
Figure 5. Modulation of signaling following acute EGFR inactivation in PC-9
cells
A: A dose-response curve for cell killing by gefitinib in subconfluent PC-9 cells
following 72 hr of treatment with the inhibitor.
B: Activated EGFR in PC-9 cells was inactivated by the addition of 2 mM of
gefitinib. At various times post-EGFR inactivation, cells were harvested and
protein lysates were analyzed by SDS-PAGE followed by western blotting
using antibodies directed against phospho-EGFRY1068 (P-EGFR), total EGFR,
cleaved-PARP (cl-PARP), full-length PARP (fl-PARP), phospho-Akt (P-Akt),
Akt, phospho-ERK1/2 (P-ERK1/2), ERK1/2, phospho-p38 (P-p38), and p38.
Times postinactivation of EGFR (in hours) are indicated at the top of each
lane, the relative migrations of the relevant proteins are indicated on the
left-hand side of each autoradiogram, and to the right of each autoradio-
gram are indicated the relative migrations of molecular weight standards.430apoptotic cell death in the population (Figure 7A; lanes 4 and
5). Then, we determined that the activation of these kinases by
OA is largely suppressed by cotreatment with the EGFR inhibitor
gefitinib (Figure 7B). Together, these observations suggest
that a balance between EGFR kinase activity and an OA-sensi-
tive phosphatase activity (possibly PP2A) contributes to the net
phosphorylation status of several of the downstream mediators
of EGFR-dependent prosurvival as well as proapoptotic sig-
naling responses. These findings also implicate cellular phos-
phatases in orchestrating the timing of signal attenuation follow-
ing acute inactivation of oncogenic kinases, such as the EGF
receptor.
Discussion
Oncogene addiction has now been well documented in several
experimental cancer models and appears to play an important
role in the clinical response to various targeted cancer therapies
that have been recently developed. However, a clear molecular
mechanism to explain the phenomenon of oncogene addiction
has been somewhat elusive. Here, we have tested a specific hy-
pothesis that oncogene addiction is associated with differences
in the attenuation rates of multiple competing prosurvival and
proapoptotic signals emanating from a single oncoprotein
source. In three different cell culture models of oncogene de-
pendency, we have observed a similar profile of rapid signal
attenuation of several key survival effectors, and a temporally
delayed accumulation of at least one proapoptotic effector,
phospho-p38 MAP kinase. This signaling profile is also
Figure 6. Effect of LY282004 on Balb-A1 ts-Src cells at 35C in 0.2% serum
A–D: Serum-starved, Balb-A1 ts-Src cells were treated with 3 mM LY294002,
and at various times posttreatment (0, 2, 4, and 6 hr) cell morphology was
documented by photomicrography.
E: Cell survival was quantitated by crystal violet staining and tabulated.CANCER CELL NOVEMBER 2006
A R T I C L Eobserved in a human lung cancer cell line, PC-9, which harbors
an activating EGF receptor mutation and is efficiently killed by
a pharmacological concentration of gefitinib that exhibits effi-
cacy in a subset of treated patients. These observations suggest
that a common signaling cascade associated with coordinated
timing of signal attenuation may underlie the apoptotic response
to acute oncogene inactivation in the context of several different
oncogenes and may also contribute to the clinical response to
kinase inhibitors in a subset of cancer patients.
Figure 7. Effect of okadaic acid and gefitinib either singly or in combination
on modulation of signaling in BaF3-EGFR(L858R) cells
BaF3-EGFR(L858R) cells were treated with either 100 nM okadaic acid (OA)
alone (lanes 1–5 in A; lanes 1–4 in B), gefitinib (GEF) alone (lanes 6–8 in A), or
100 nM OA together with 2 mM gefitinib (lanes 5–8 in B). At various periods of
time posttreatment (as indicated at the top of each lane), cells were har-
vested and their proteins were analyzed by SDS-PAGE followed by western
blotting using antibodies directed against phospho-EGFRY1068 (P-EGFR),
EGFR, phospho-Akt (P-Akt), Akt, phospho-ERK1/2 (P-ERK1/2), ERK1/2, phos-
pho-p38 (P-p38), and p38. The relative migrations of the relevant proteins
are indicated on the left-hand side of each autoradiogram, and to the right
of each autoradiogram are indicated the relative migrations of molecular
weight standards.CANCER CELL NOVEMBER 2006In this model of differential signal attenuation (Figure 8), we
propose that, upon disruption of oncogenic activity, a temporary
imbalance in proapoptotic and prosurvival signals results from
the fact that at least some of the established survival factors,
such as ERKs, Akt, and STAT3/5 undergo relatively rapid inacti-
vation, whereas proapoptotic signals can persist long enough to
drive an apoptotic outcome in the absence of counteracting sur-
vival signals. This model implies that a temporal window exists
during which lingering ‘‘unchecked’’ proapoptotic signals ema-
nating from an oncoprotein that has recently been inactivated
cause the cell to pass a commitment point toward apoptosis.
In fact, experimental studies have demonstrated that commit-
ment to an apoptotic outcome can occur within only a few hours
following the initiation of an apoptotic signal (Brunet et al., 1998).
Our observation (especially in the PC-9 system) that phospho-
AKT levels are rapidly inactivated for a brief period in lung cancer
cells treated with the EGF receptor kinase inhibitor gefitinib, and
then recover prior to apoptosis (Figure 5B), is consistent with
a model wherein a transient loss of prosurvival signaling is
Figure 8. Proposed model of oncogene addiction
A: A graphical depiction of the proposed role of differential signal attenua-
tion in creating a temporal window during which apoptotic signals persist in
the absence of prosurvival signals following acute oncogene inactivation to
promote cell death.
B: This model depicts the proposed role of differential signal attenuation in
the cell death response to acute inactivation of oncogenic EGFR (EGFR*)
upon which a tumor cell has become dependent. The upper panel illus-
trates the oncogene ‘‘addicted’’ state in which cells survive, and the lower
panel illustrates the shift in the balance of prosurvival and proapoptotic
signaling shortly following EGFR inactivation. Red, ‘‘off’’; green, ‘‘on.’’431
A R T I C L Esufficient to shift the survival-death balance and to produce an
apoptotic outcome. In addition, we have determined that tran-
sient transfection of cultured NIH3T3 cells with an activated
Ras mutant that is specifically defective for interaction with the
PI-3 kinase/Akt survival pathway causes apoptosis in a substan-
tial fraction of transfected cells, whereas activated Ras that
retains this interaction does not cause apoptosis (Figure S4).
While there are potentially multiple mechanisms that could
contribute to a transient signaling imbalance following onco-
gene inactivation, the phosphatase inhibitor studies that we
have described point to an important role for cellular phospha-
tases in determining the ‘‘steady-state’’ levels of phosphoryla-
tion of the various well-studied downstream effectors of many
oncogenic kinases. These findings also implicate phosphatases
in determining the temporal kinetics of effector activation and
deactivation. While OA is an admittedly blunt tool for elucidating
the precise mechanism by which phosphatases might contrib-
ute to differential signal attenuation, other reported studies sim-
ilarly support a role for phosphatase activity in determining the
temporal ordering of signal activation and deactivation. For ex-
ample, previous studies of an apoptosis model in cultured PC12
neural cells that undergo apoptosis upon withdrawal of nerve
growth factor revealed a similar temporally coordinated cas-
cade of ERK1/2 inactivation followed by an accumulation of
phospho-p38 prior to apoptosis (Xia et al., 1995). In addition,
Akt has been reported to negatively regulate p38 activity, indi-
rectly through the ASK1 and MKK3/6 kinases (Ichijo et al.,
1997; Kim et al., 2001). Notably, protein phosphatase 5 (PP5),
an OA-sensitive phosphatase, reportedly dephosphorylates
ASK1 and inhibits ASK1 signaling (Morita et al., 2001), thereby
providing another potential mechanism by which phosphatase
activity could contribute to the timing of signal attenuation.
These findings, together with our findings, suggest that a shared
profile of orchestrated attenuation of prosurvival and proapop-
totic signals may play an important role in a variety of apoptosis
settings.
We recognize that we have only examined a relatively small
subset of the numerous downstream effectors that have been
previously implicated in the response to activating oncoproteins
such as Src, EGF receptor, and BCR-ABL. Consequently, it is
a near certainty that any differential signal attenuation mecha-
nisms that may be operating in the models we have examined
are more complex than the simple model we have described.
Moreover, we note that multiple distinct mechanisms of onco-
gene addiction may be contributing to this phenomenon in the
various contexts in which it has been observed. For example,
the proliferative arrest and differentiation responses to onco-
gene inactivation that have been reported in some settings
may involve distinct mechanisms, although it remains possible
that an analogous signaling imbalance of a different nature
could be contributing to those outcomes.
The proposed model of oncogene addiction differs somewhat
from previous descriptions of the phenomenon in that it implies
that the apoptotic outcome in response to oncogene inactiva-
tion is an active process that requires proapoptotic signals de-
rived from the oncoprotein, as opposed to a passive process
in which a cell that is dependent on an oncogene-derived sur-
vival signal defaults to an apoptotic death upon inactivation of
that oncogene. It is well established that several oncoproteins,
including Ras and Src, can produce proapoptotic outputs in
some contexts (Arber, 1999; Webb et al., 2000). Moreover,432most of the well-studied oncoproteins, such as EGF receptor,
BCR-ABL, and Ras, promote the activation of numerous down-
stream effector pathways, and in each case, some of these have
been linked to proapoptotic outcomes depending on the con-
text. Several potential molecular mechanisms to account for
a proapoptotic outcome have been reported. Thus, Ras can
be proapoptotic via an interaction with the effector target
Nore1 (Vos et al., 2003). Similarly, the EGF receptor can bind di-
rectly to the so-called ‘‘death ligand’’ FAS/CD95 (Reinehr et al.,
2003). In addition, Src can induce apoptosis in B lymphocytes
via engagement of the CD20 surface protein (Hofmeister et al.,
2000). Thus, it is reasonable to expect that the state of a cell ex-
pressing an activated oncoprotein reflects the net balance of
multiple diverse signaling pathways that have been engaged.
Accumulating evidence indicates that many tumor cells are
poised on the edge of an apoptotic event and that tumor cells
have an increased tendency to undergo apoptosis. In most tu-
mor cells, the balance between prosurvival and proapoptotic
signals clearly favors a survival outcome; however, it is easy to
imagine that a temporary imbalance in those pathways in the ini-
tial hours following inactivation of the upstream source of those
signals could shift cells toward an apoptotic event, particularly if
the survival signals dissipate rapidly. Indeed, we have observed
that treatment of PC-9 lung cancer cells for as little as 30 min
(followed by drug washout) is sufficient to kill approximately
half of the cells (Figure S5). Moreover, the differential signal at-
tenuation model may also explain the emerging concept that tu-
mor cells in which a kinase has undergone mutational activation
or is overexpressed are especially sensitive to the killing effects
of drugs that target those kinases. Specifically, the model sug-
gests that increased kinase activity is associated with increased
proapoptotic (as well as prosurvival) output, and that this exces-
sive proapoptotic activity contributes to the cell death observed
following acute inactivation of the oncogenic kinase. In support
of such a conclusion, we have observed that cultured lung
cancer cells that are killed by gefitinib treatment can be more
efficiently killed in the presence of 10% serum, which contains
EGF, the receptor ligand (Figure S6). This may reflect a role for
EGF in driving higher levels of an apoptotic output from muta-
tionally activated EGFR. In addition, this could explain why
most normal cells, in which these same kinases are not signaling
excessively, are typically not killed by treatment with a drug that
targets the kinase. Thus, this differential signal attenuation
model raises questions about the appropriateness of the term
‘‘addiction’’ in this setting, which seemingly implies a passive
dependency on the oncogenic kinase. As an alternative, we
have proposed the term ‘‘oncogenic shock’’ to describe the pro-
posed signaling imbalance that can accompany acute onco-
gene inactivation, and which ascribes an active proapoptotic
role to the oncogenic kinase in the consequent cell death
response (Sharma et al., 2006). Notably, with such a mechanism,
it may not be relevant whether the oncogenic lesion is an initiat-
ing event or a late event in tumorigenesis; however, its predom-
inance in the tumor may be critical in determining whether tar-
geting it produces a significant clinical response.
The studies we have performed may also have clinical impli-
cations regarding the use of cancer therapies that target onco-
genic kinases. For example, coadministration of a drug that
promotes cell cycle arrest might suppress apoptosis that would
normally be triggered by acute inactivation of an oncogenic
kinase, a mechanism that has potentially contributed to theCANCER CELL NOVEMBER 2006
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hibitors are administered together with conventional chemo-
therapy drugs. These findings also raise the possibility that
drugs directed against downstream signaling proteins that shift
the balance of kinase-mediated proapoptotic and prosurvival
signals may also have therapeutic value. Differential signal at-
tenuation may also contribute to the acquisition of drug resis-
tance that frequently develops in patients during treatment
with selective kinase inhibitors if genetic or epigenetic changes
allow cells to survive during a temporal window between the dis-
sipation of prosurvival and proapoptotic signals. These findings
also raise the possibility that ‘‘on-off cycles,’’ as opposed to
continuous treatment, with targeted kinase inhibitors may be
more beneficial to patients by allowing for more ‘‘windows of
opportunity’’ for the inhibitors to produce a transient signaling
imbalance that leads to apoptotic cell death. Thus, in contrast
to traditional chemotherapeutic agents that appear to trigger
a DNA damage response, the emergence of small molecules
that target specific components of signaling pathways may in-
volve distinct mechanisms of cancer cell death. Further insights
into these mechanisms may allow optimal clinical application of
these new molecularly targeted agents.
Experimental procedures
Cell lines
TonB210.1 cells expressing the tetracycline-inducible Bcr-Abl oncogene
were kindly provided by George Q. Daley (Children’s Hospital, Boston) and
were maintained as described previously (Klucher et al., 1998). BaF3-
EGFR expressing the gefitinib-sensitizing L858R mutant EGFR was main-
tained as described previously (Jiang et al., 2005). PC-9 cells expressing
the gefitinib-sensitizing deletion mutation (DE746-A750) were kindly pro-
vided by Dr. Kazuto Nishio (National Cancer Center Hospital, Tokyo) and
were maintained as described previously (Koizumi et al., 2005). Balb A1-ts
src cells expressing the temperature-sensitive v-src oncogene and J2
v-src 3T3 cells expressing the retroviral v-src oncogene were propagated
in DMEM containing 10% fetal bovine serum (FBS) and penicillin and strep-
tomycin (100 U/ml and 100 mg/ml, respectively). NIH 3T3 mouse fibroblasts
were maintained in DMEM supplemented with 10% calf serum and penicillin
and streptomycin (100 U/ml and 100 g/ml, respectively).
Antibodies
HRP-conjugated anti-phosphotyrosine antibody and rabbit polyclonal anti-
body against phospho-Akt (Ser473) were purchased from Biosource. The
rabbit polyclonal antibody directed against EGFR was from Santa Cruz
Biotechnology. Mouse monoclonal antibodies against phospho-EGFR
(Tyr1068), phospho-STAT5 (Tyr694), and cleaved PARP as well as rabbit
polyclonal antibodies against Bcr, phospho-p44/42 ERK kinase (Thr202/
Tyr204), phospho-Akt (Ser473), phospho-Src (Tyr416), phospho-STAT3
(Tyr705), full-length PARP, and phospho-p38 (Thr180/Tyr182), and anti-
bodies directed against their nonphosphorylated counterparts, were pur-
chased from Cell Signaling Technology. Anti-BrdU antibody was from Becton
Dickinson. Secondary antibodies included HRP-conjugated anti-mouse and
anti-rabbit antibodies and were purchased from Cell Signaling Technology.
The FITC-conjugated anti-mouse antibody was from Vector Laboratories.
Inhibitors
Gefitinib was kindly provided be Astra-Zeneca Pharmaceuticals (Maccles-
field, UK) and was resuspended in DMSO at a stock concentration of
2 mM. OA, LY282004, and the Src-specific inhibitor SU6656 were purchased
from Calbiochem and resuspended in DMSO at a stock concentration of 0.1,
50, and 5 mM, respectively. All inhibitors were stored in small aliquots
at 220C.
Induction of apoptosis by oncogene inactivation
Cells were plated in their respective maintenance media and used for exper-
imentation when they had reached a confluence of 70%. Apoptosis wasCANCER CELL NOVEMBER 2006induced in each system as described below. At various times after induction
of apoptosis, the cells were harvested, and the activation state of the relevant
signal transducers was assessed by SDS-PAGE followed by western
blotting.
Bcr-Abl
The Bcr-Abl protein was induced in TonB-210.1 cells by incubating them for
18 hr with 1 mg/ml of doxycycline in their growth medium (RPMI-1640 con-
taining sodium pyruvate, penicillin-streptomycin, and 10% FBS). Inactivation
of Bcr-Abl was accomplished by the removal of doxycycline from the growth
medium. To this end, cells were collected by centrifugation, washed three
times in media without doxycycline, and resuspended in media without doxy-
cycline, and at various times (0, 1, 2, 4, 8, 24, 48, and 72 hr) cells were
harvested for analysis.
Src
Exponentially growing Balb A1-ts src cells growing at 35C in DMEM contain-
ing 10% FBS were washed once with DMEM containing 0.2% FBS and then
placed in DMEM containing 0.2% FBS at 35C for a period of 18 hr. V-src was
inactivated by replacing the medium on the cells with DMEM containing
0.2% FBS that had been prewarmed to 39.5C. At various times postin-
activation of src (0, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr), cells
were harvested for analysis.
Exponentially growing J2 v-src 3T3 cells were washed once with serum-
free DMEM and then placed in serum-free DMEM for a period of 18 hr. Sub-
sequently, they were treated with 3 mM SU6656 (in DMSO) that was added
directly to the serum-free growth medium. The untreated controls received
an equivalent volume of DMSO. Following treatment with SU6656, cells
were harvested at 0, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr.
EGFR
Exponentially growing BaF3-EGFR(L858R) and PC-9 cells were treated with
2 mM gefitinib (in DMSO) that was added directly to the growth medium
(RPMI-1640 containing sodium pyruvate, penicillin-streptomycin, and 10%
FBS). The untreated controls received an equivalent volume of DMSO. Fol-
lowing treatment with gefitinib, cells were harvested at 0, 4, 8, 24, 36, 48,
60, and 72 hr. In experiments using BaF3-EGFR(L858R), which involved
the use of OA shown in Figure 8, OA was used at a final concentration of
100 nM and was added either by itself or together with gefitinib for the appro-
priate amounts of time as indicated in the figure.
Transfection and apoptosis assays
Transfection of NIH 3T3 mouse fibroblasts was performed with an electropo-
rator using reagents and protocols provided by the manufacturer (Amaxa).
Cells were transfected with 1 mg of vector, H-RasV12, or H-RasV12T35S (White
et al., 1995) together with a GFP plasmid provided by Amaxa (to monitor
transfection efficiency). Six to eight hours following transfection, cells were
washed and transferred to DMEM containing 0.1% FBS. At this time, the
transfection efficiency was also assayed by fluorescence microscopy of
GFP signal and determined to be approximately 80%–90%. Cell number
and apoptosis were assayed 40 hr later. The number of cells that adhered
to the dish is presented as a percentage of cells relative to vector-transfected
controls (Figure S4A). Apoptotic cells were quantitated using fluorescence-
activated cell sorting (FACS) according to the manufacturer’s protocol (Bec-
ton Dickinson). Cells were incubated with cell-labeling reagent BrdU (Amer-
sham-Pharmacia) at 37C for 30 min. Subsequently, all cells (adherent and
floating) were collected, washed with PBS, and fixed in 80% ethanol. DNA
was denatured for 30 min with 2 M HCl/0.5% Triton X-100 and neutralized
with 0.1 M NaB4O7  10 H2O (pH 8.5), before incubation with anti-BrdU anti-
body (1:500) and a FITC-conjugated goat anti-mouse secondary antibody
(1:50). Cells were stained with 5 mg/ml propidium iodide (Sigma) and treated
with RNase A (Sigma) prior to two-dimensional FACS analysis using
CELLQUEST software (Becton Dickinson). The number of gated cells in
the sub-G1 population is presented as the ratio of apoptotic cells to vector-
transfected controls (Figure S4B).
Cell harvesting and protein analysis
At each time point, cells were placed on ice, scraped in their own media, and
collected by low-speed refrigerated centrifugation. Cell pellets were then433
A R T I C L Ewashed once in ice-cold PBS and stored at280C until ready for analysis by
SDS-PAGE and immunoblotting using standard procedures.
Supplemental data
The Supplemental Data include six supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/5/
425/DC1/.
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